Early treatment with nusinersen can mean better outcomes for babies

(IOS Press) Spinal muscular atrophy (SMA) is a genetic disease that affects motor neurons in the spinal cord, resulting in muscle atrophy and widespread weakness that eventually impair swallowing and breathing. A new study in the Journal of Neuromuscular Diseases finds that children with SMA type 1 can achieve improvements in motor function after six months of treatment with the drug nusinersen, particularly when treatment began before seven months of age.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news